CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
用于多发性骨髓瘤的 CAR-T 细胞、双特异性抗体与抗体偶联药物：最新进展
英文原题：Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update.
查看英文原题
Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
对目前可用的有效疗法难治的多发性骨髓瘤患者预期生存期短。利用骨髓瘤免疫特征和微环境知识的治疗方式，如嵌合抗原受体（CAR）T淋巴细胞、双特异性抗体（bsAbs）和抗体药物偶联物（ADCs），已在早期试验中显示出潜力。基于2期研究数据，抗B细胞成熟抗原CAR-T 产品idecabtagene vicleucel（ide cel）和ADC belantamab mafodotin（belamaf）目前已在复发/难治性环境中获批。bsAbs已显示出快速且深度缓解的前景。在本综述中，我们总结了来自临床试验的这些治疗的现有证据。
展开英文摘要原文
Patients with multiple myeloma who are refractory to currently available effective therapies have short expected survival. Modalities harvesting the knowledge of the immune characteristics and microenvironment of myeloma such as chimeric antigen receptor (CAR) T-lymphocytes, bispecific antibodies (bsAbs), and antibody-drug conjugates (ADCs) have shown potential in early phase trials.
Based on data from phase 2 studies, idecabtagene vicleucel (ide cel), an anti-B-cell maturation antigen CAR T-product and belantamab mafodotin (belamaf), an ADC are currently approved in the relapsed/refractory setting. bsAbs have shown promise with quick and deep responses. In this review, we summarize the available evidence on these treatments from clinical trials.
论文信息
- 作者
- Lakshman A、Kumar SK
- 第一作者单位
- Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.United States
- 通讯作者单位
- Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.United States
- 文献类型
- 综述
- 期刊
- American journal of hematology2022 Jan 1
- 原文标识
- PubMed 34661922 · DOI 10.1002/ajh.26379